Healthcare >> CEO Interviews >> November 18, 2002
HARRY A. DUGGER III is the President and Chief Executive Officer
of NovaDel Pharma Inc. (formerly Flemington Pharmaceutical
Corporation). Dr. Dugger is the founder of Flemington
Pharmaceutical and the inventor of the lingual spray and bite
capsule technology, which the company is developing and marketing
as Immediate-Immediate Release (I2R). Dr. Dugger received his PhD
from the University of Michigan and was an NIH Postdoctoral
Fellow at the University Of Zurich, working on the chemical
structure of the colors in red beets and on pseudo-aromatic
compounds. He joined Sandoz Pharmaceuticals in the US in 1964,
where he was responsible for drug development primarily in the
areas of biopharmaceuticals and drug metabolism. In 1980, he
resigned to join Baurs-Krey Associates in New York, and in 1982
he founded Pharmaconsult, the precursor to Flemington. Through
Pharmaconsult, Dr. Dugger advised clients on all aspects of drug
development, including but not limited to manufacturing of drug
substances and drug products (cGMP), toxicity studies, clinical
trials, filing of ANDAs, INDs, NDAs, as well as co-founding LAB
Inc. in the US to market the clinical services of LAB GmbH
(Germany) to US-based pharmaceutical companies. Since 1996, Dr.
Dugger has spent much of his time in developing a number of I2R
formulations and running studies to demonstrate their utility. Profile
and bring us up to date on some of the most important things that
you've done lately?
Dr. Dugger: NovaDel started in 1982 as a
